2021
Emerging Role of Immune Therapy in HCC
Stein S. Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions 2021, 05: 277-282. DOI: 10.1055/s-0041-1722932.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsHepatocellular carcinomaImmune therapySingle-agent PD-1 inhibitionVascular endothelial growth factor inhibitionMultiple tyrosine kinase inhibitorAbstract Hepatocellular carcinomaPrevalent cancer diagnosesUnprecedented response ratesPD-1 inhibitionAdvanced hepatocellular carcinomaGrowth factor inhibitionAdvanced diseaseDurable responsesPD-1Combination therapyTreatment optionsFactor inhibitionResponse rateTherapy drugsPatientsKinase inhibitorsTherapyCancer diagnosisModest improvementA phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
He A, Kim A, Toskich B, Mody K, Kim K, Stein S, Goyal L, Abrams T, Brown D, Goff L, Kim R, Parikh N, Sandow T, Johnson D, Iyer R, Petroziello M, Krishnamurthi S, Martin C, Jiang Y, Akhter N. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2021, 39: tps358-tps358. DOI: 10.1200/jco.2021.39.3_suppl.tps358.Peer-Reviewed Original ResearchPhase II studyProgression-free survivalHepatocellular carcinomaII studyArm BTARE treatmentBCLC stage B hepatocellular carcinomaAntitumor T-cell activityStage B hepatocellular carcinomaRandomized phase II studyMyeloid-derived suppressor cellsPD-L1 expression levelsIntermediate-stage hepatocellular carcinomaT cell receptor repertoireB hepatocellular carcinomaIntermediate-stage HCCMain secondary objectivesFirst-line treatmentPretreatment liver biopsyRegulatory T cellsT cell infiltrationAdvanced hepatocellular carcinomaDendritic cell maturationT cell activityPatient-reported outcomes
2020
PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States.
Uhlig J, Stein S, Kim K. PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States. Journal Of Clinical Oncology 2020, 38: e16647-e16647. DOI: 10.1200/jco.2020.38.15_suppl.e16647.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalPD-1Multivariable analysisLiver disease risk factorsCox proportional hazards modelBilirubin resultsAdvanced hepatocellular cancerClinical performance statusLiver disease complicationsOverall survival benefitDisease risk factorsDeath protein 1Longer overall survivalOncological treatment strategiesProportional hazards modelDe-identified databaseSystemic sorafenibAdult patientsHCC resectionPatient demographicsPerformance statusSurvival benefitIndependent prognosticator
2019
LBA7 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Hsu C, Lee M, Lee K, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Huang C, He R, Ryoo B. LBA7 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: ix187. DOI: 10.1093/annonc/mdz446.006.Peer-Reviewed Original ResearchUnresectable hepatocellular carcinomaHepatocellular carcinomaMedian PFSPrimary endpointArm AF. Hoffmann-La RocheHoffmann-La RocheOno PharmaceuticalGenentech/RocheIndependent review facilityObjective response rateTolerable safety profileProgression-free survivalRoche/GenentechGr 3CI 3.6Improved PFSMedian DoRMedian followRECIST 1.1Checkpoint inhibitorsDurable responsesFree survivalUnacceptable toxicityAdverse eventsLBA39 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Lee M, Ryoo B, Hsu C, Numata K, Stein S, Verret W, Hack S, Spahn J, Liu B, Abdullah H, He R, Lee K. LBA39 Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Annals Of Oncology 2019, 30: v875. DOI: 10.1093/annonc/mdz394.030.Peer-Reviewed Original ResearchGenentech/RocheUnresectable hepatocellular carcinomaHepatocellular carcinomaMedian PFSPrimary endpointArm AF. Hoffmann-La RocheComplete responsePartial responseHoffmann-La RocheOno PharmaceuticalDisease control rateIndependent review facilityObjective response rateTolerable safety profileProgression-free survivalDuration of responseEli LillyMedical writing assistanceGr 3Bristol-Myers SquibbEisai Inc.Improved PFSMedian DoRRECIST 1.103:36 PM Abstract No. 320 Survival analysis of patients with hepatitis c and hepatocellular carcinoma receiving interventional oncology therapies and direct-acting antivirals with 12-week sustained viral response
Kamp W, Sellers C, Stein S, Lim J, Kim H. 03:36 PM Abstract No. 320 Survival analysis of patients with hepatitis c and hepatocellular carcinoma receiving interventional oncology therapies and direct-acting antivirals with 12-week sustained viral response. Journal Of Vascular And Interventional Radiology 2019, 30: s141-s142. DOI: 10.1016/j.jvir.2018.12.388.Peer-Reviewed Original ResearchImpact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma.
Kamp W, Sellers C, Stein S, Lim J, Kim H. Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma. Journal Of Clinical Oncology 2019, 37: 397-397. DOI: 10.1200/jco.2019.37.4_suppl.397.Peer-Reviewed Original ResearchHepatitis C viral infectionDAA therapyOverall survivalHepatocellular carcinomaMultivariable analysisViral responseHCC patientsTumor locationTreatment allocationHigher OSMultivariable Cox proportional hazards modelsUrban tertiary care hospitalCox proportional hazards modelHCV-negative patientsChild-Pugh scoreMedian overall survivalSustained viral responseTertiary care hospitalC viral infectionKaplan-Meier curvesProportional hazards modelDAA patientsHCV patientsHepatitis CMELD score
2018
150O Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study
Lee K, Hsu C, Lee M, Ryoo B, Verret W, He A, Kwan A, Liu B, Iizuka K, Stein S. 150O Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study. Annals Of Oncology 2018, 29: ix47. DOI: 10.1093/annonc/mdy432.002.Peer-Reviewed Original ResearchLBA26 Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Pishvaian M, Lee M, Ryoo B, Stein S, Lee K, Verret W, Spahn J, Shao H, Liu B, Iizuka K, Hsu C. LBA26 Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Annals Of Oncology 2018, 29: viii718-viii719. DOI: 10.1093/annonc/mdy424.028.Peer-Reviewed Original ResearchSafety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stein S, Pishvaian M, Lee M, Lee K, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K, Ryoo B. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2018, 36: 4074-4074. DOI: 10.1200/jco.2018.36.15_suppl.4074.Peer-Reviewed Original ResearchThe effect of socioeconomic factors on the outcome of hepatocellular carcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.Peer-Reviewed Original ResearchMedian overall survivalCancer-directed treatmentOverall survivalHepatocellular carcinomaPrivate insurancePrimary insuranceInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingMultivariate Cox proportional analysisCox proportional analysisTertiary care hospitalOS of patientsKaplan-Meier curvesProportional hazard modelingSocioeconomic factorsMedian OSSurvival benefitCare hospitalConsecutive patientsAJCC stageCancer RegistryMean ageTreatment courseSurvival advantage